PZ18753b-NC

PZ18753b-NC is a small molecule research compound used as a negative control for the PROTAC (Proteolysis-Targeting Chimera) PZ18753b. It was developed by researchers at the University of Florida, MD Anderson Cancer Center, and Ohio State University. Structurally, it is derived from the dual Bcl-2/Bcl-xL inhibitor navitoclax but is modified to be incapable of recruiting the Von Hippel-Lindau (VHL) E3 ubiquitin ligase. In preclinical studies of chronic lymphocytic leukemia (CLL), particularly in models of venetoclax resistance, PZ18753b-NC serves as a critical tool to demonstrate that the therapeutic activity of the parent PROTAC is driven by protein degradation rather than simple target inhibition. While it retains binding affinity for Bcl-2 and Bcl-xL, it does not facilitate their proteasomal degradation.